Amsoki-cel produced responses in two-thirds of advanced melanoma patients. Can Obsidian make TIL therapy easier to deliver?
Obsidian’s amsoki-cel delivered a 67% response rate in advanced melanoma while testing whether engineered TIL therapy can work without systemic IL-2.